Serum cholesterol and treatment response in patients with depressive disorder

2011 ◽  
Vol 26 (S2) ◽  
pp. 666-666
Author(s):  
T. Novak ◽  
M. Bares
Keyword(s):  
Depressive Disorder ◽  
Clinical Response ◽  
Serum Cholesterol ◽  
Rating Scale ◽  
Elevated Serum ◽  
Response To Treatment ◽  
Madrs Score ◽  
Cholesterol Levels ◽  
Elevated Cholesterol ◽  
New Treatment

IntroductionThe previous studies reported that elevated serum cholesterol levels (≥ 200 mg/dl) were associated with poorer response to fluoxetine and nortiptyline treatment in patients with depression.AimsThe aim of this study was to examine the relationship between pretreatment serum cholesterol levels and clinical response to treatment with different antidepresants among inpatients with depressive disorder.MethodsOne hundred and four inpatients with depressive disorder who did not respond to previous treatment were enrolled in a six-week open study. New treatment (different antidepressant monotherapies, combinations or augmentations) was chosen according to clinical judgment. Serum cholesterol levels were obtained before starting new treatment. Cholesterol levels were classified as either elevated (≥ 200 mg/dl) or nonelevated. Clinical response was defined as ≥ 50% decrease in the Montgomery Åsberg Depression Rating Scale (MADRS) score at endpoint compared to baseline.ResultsForty-six patient (44%) were classified as having elevated cholesterol levels at baseline. Patients with elevated cholesterol levels did not significantly differ in gender ratio, baseline MADRS score, duration of current episode and number of previous episodes but were significantly older than patients with nonelevated cholesterol levels. After adjusting for age, gender, and Body Mass Index (BMI), we did not find significant differences in response rate and as well as in the pretreatment-posttreatment change in MADRS between patients with elevated cholesterol and patients with nonelevated levels.ConclusionWe did not demonstrate association between pretreatment cholesterol level and response to treatment in depressive disorder.Study was supported by the grant NS10368 IGA MZ CR.

scholarly journals Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials

CNS Spectrums ◽  
2014 ◽  
Vol 20 (2) ◽  
pp. 148-156 ◽  
Author(s):  
Stuart A. Montgomery ◽  
Carl P. Gommoll ◽  
Changzheng Chen ◽  
William M. Greenberg
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Extended Release ◽  
Rating Scale ◽  
Pooled Analysis ◽  
Major Depressive ◽  
Double Blind ◽  
Madrs Score ◽  
Wide Range ◽  
Remission Rates

Introduction/ObjectivePost hoc analyses were conducted to evaluate the efficacy of levomilnacipran extended-release (ER) in subgroups of patients with major depressive disorder (MDD).MethodsData were pooled from 5 completed Phase II/III studies. Patients were categorized by sex, age, MDD duration, recurrence of MDD, current episode duration, number of prior episodes, and baseline Montgomery–Åsberg Depression Rating Scale (MADRS) score. Efficacy was evaluated by MADRS least squares (LS) mean change from baseline, response (MADRS improvement ≥50%), and remission (MADRS ≤10).ResultsIn the pooled population, treatment with levomilnacipran ER versus placebo resulted in greater improvement in MADRS score (−15.8 versus −12.9; LS mean difference, −2.9; P < .001) and higher response rates (44.7% versus 34.5%; P < .001). Comparable treatment effects were found in most subgroups. Remission rates in the overall population were higher for levomilnacipran ER versus placebo (27.7% versus 21.5%; P < .05); notably high remission rates were seen in patients with baseline MADRS score < 30 (48.8% versus 28.9%; P < .001).DiscussionClinically meaningful improvements in depressive symptoms were found across subgroups, including statistically significant outcomes for both response and remission.ConclusionLevomilnacipran ER was efficacious across a wide range of MDD patients, including men and women, ages 18–78, with varying histories and symptom severity.

Escitalopram Versus SNRI Antidepressants in the Acute Treatment of Major Depressive Disorder: Integrative Analysis of Four Double-Blind, Randomized Clinical Trials

CNS Spectrums ◽  
2009 ◽  
Vol 14 (6) ◽  
pp. 326-333 ◽  
Author(s):  
Susan G. Kornstein ◽  
Dayong Li ◽  
Yongcai Mao ◽  
Sara Larsson ◽  
Henning F. Andersen ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Randomized Clinical Trials ◽  
Rating Scale ◽  
Severe Depression ◽  
Major Depressive ◽  
Double Blind ◽  
Madrs Score ◽  
Treatment Difference

AbstractIntroduction: Recent data suggest that escitalopram may be more effective in severe depression than other selective serotonin reuptake inhibitors.Methods: Individual patient data from four randomized, double-blind comparative trials of escitalopram versus a serotonin/norepinephrine reuptake inhibitor (SNRI) (two trials with duloxetine and two with venlafaxine extended release) in outpatients (18–85 years of age) with moderate-to-severe major depressive disorder were pooled. The primary efficacy parameter in all four trials was mean change in the Montgomery-Asberg Depression Rating Scale (MADRS) score.Results: Significantly fewer escitalopram (82/524) than SNRI (114/527) patients prematurely withdrew from treatment due to all causes (15.6% vs. 21.6%, Fisher Exact: P=.014) and adverse events (5.3% vs. 12.0%, Fisher Exact: P <.0001). Mean reduction in MADRS score from baseline to Week 8 was significantly greater for the escitalopram group versus the SNRI group using the last observation carried forward (LOCF) approach [mean treatment difference at Week 8 of 1.7 points (P <.01)]. Similar results were observed in the severely depressed (baseline MADRS score ≥30) patient subset (mean treatment difference at Week 8 of 2.9 points [P <.001, LOCF]). Observed cases analyses yielded no significant differences in efficacy parameters.Conclusion: This pooled analysis indicates that escitalopram is at least as effective as the SNRIs (venlafaxine XR and duloxetine), even in severe depression, and escitalopram treatment was better tolerated.

Cholesterol-induced Thrombogenicity of the Vessel Wall: Inhibitory Effect of Fluvastatin

2002 ◽  
Vol 87 (04) ◽  
pp. 748-755 ◽  
Author(s):  
Marina Camera ◽  
Vincenzo Toschi ◽  
Carmen Comparato ◽  
Roberta Baetta ◽  
Francesca Rossi ◽  
...  
Keyword(s):  
Serum Cholesterol ◽  
Transcriptional Activation ◽  
Vessel Wall ◽  
Arterial Wall ◽  
Thrombus Formation ◽  
Plasma Cholesterol ◽  
Elevated Serum ◽  
Rabbit Model ◽  
Cholesterol Levels ◽  
Platelet Deposition

SummaryHigh cholesterol levels are a known risk factor for coronary events. The molecular links between high serum cholesterol and the increased thrombogenicity of the arterial wall are still matter of investigation. In the present study we investigate the relationship between plasma cholesterol, thrombus formation and TF expression in a atherosclerotic rabbit model.Hypercholesterolemic rabbits showed a pronounced TF staining as well as NF-κB activation in the aortic arch. A consistent vessel wall platelet deposition was also observed. Treatment with fluvastatin reduced lipid accumulation, TF overexpression (-60%), NF-κB activation, and platelet deposition (-56%). In vitro studies showed that the drug upregulated IκBa in unstimulated as well as in TNFa-stimulated cells and also impaired the TNF-α-induced Cdc42 prenylation, indicating that fluvastatin interferes with the transcriptional activation of TF gene.These results indicate that the prothrombotic phenotype of arterial wall, associated with elevated serum cholesterol levels, is mediated by TF overexpression. Fluvastatin treatment reduces the prothrombotic tendency by inhibiting TF synthesis.

Serum Uric Acid and Cholesterol Levels in Mongoloid and Non-Mongoloid Oligophrenics

1966 ◽  
Vol 112 (482) ◽  
pp. 91-94 ◽  
Author(s):  
L. M. Dalderup ◽  
H. Affourtit-Leeuw ◽  
P. A. F. van der Spek ◽  
G. H. M. Keller ◽  
H. J. Duin ◽  
...  
Keyword(s):  
Uric Acid ◽  
Serum Uric Acid ◽  
Serum Cholesterol ◽  
Dietary Fat ◽  
Acid Level ◽  
Serum Cholesterol Level ◽  
Serum Uric Acid Level ◽  
Elevated Serum ◽  
Cholesterol Levels ◽  
Fat Composition

A number of observations have been published with regard to elevated serum uric acid levels in patients with atherosclerotic (Eidlitz, 1961, 1962) and coronary disease (Gertler, Garn and Levine, 1951) and hyperuricaemia after myocardial infarction (Dreyfuss, 1959; Kohn and Prozan, 1959). Work has also been done on dominant traits for hyperuricaemia together with hypercholesterolaemia (Adlersberg, 1949; Harris-Jones, 1957; Salvini and Verdi, 1959; Schoenfeld and Goldberger, 1963). A greater incidence of cardiovascular diseases among gouty patients than among others has been noted (Gertler and Oppenheimer, 1953), as well as a tendency for spontaneous changes in the serum cholesterol level to be associated with changes of similar direction and magnitude in the serum uric acid level (Schoenfeld and Goldberger, 1963). In view of all these observations, an investigation was undertaken to ascertain whether the serum uric acid levels change with dietary fat composition as do the serum cholesterol levels.

Serum Cholesterol in Patients with Obsessive Compulsive Disorder during Treatment with Behavior Therapy and SSRI or Placebo

2000 ◽  
Vol 30 (1) ◽  
pp. 27-39 ◽  
Author(s):  
Helmut Peter ◽  
Susanne Tabrizian ◽  
Iver Hand
Keyword(s):  
Panic Disorder ◽  
Behavior Therapy ◽  
Serum Cholesterol ◽  
Obsessive Compulsive ◽  
Double Blind ◽  
Compulsive Disorder ◽  
Cholesterol Levels ◽  
Elevated Cholesterol ◽  
Obsessive Compulsive Disorders ◽  
Compulsive Disorders

Objective: Patients with panic disorder are reported to have elevated cholesterol levels. There is also some evidence that cholesterol elevation is not so much a specific condition in panic disorder but is generally associated with anxiety. So far, there is little data on cholesterol levels in patients with obsessive compulsive disorders (OCD) which is also classified as anxiety disorder. Method: Thirty-three patients with OCD participated in the study. Serum cholesterol was measured as pretreatment and at the end of a ten-week treatment-period. All patients received behavior therapy and, in a double-blind fashion, fluvoxamine or placebo. Severity of OCD was assessed by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Results: Pretreatment cholesterol values of OCD patients were compared with cholesterol levels of thirty panic disorder patients and thirty normal controls. OCD patients had elevated cholesterol levels comparable with those of panic disorder patients. Cholesterol levels decreased significantly from pre- to posttreatment. OCD patients with high cholesterol levels (≥ 240 mg/dl, n = 7) could make best use of the treatment whereas patients with desirable cholesterol levels (< 200 mg/dl, n = 11) did not change their cholesterol during treatment. Conclusions: Our data support the assumption that not only panic disorder but also other anxiety disorders, e.g., obsessive compulsive disorders, may be associated with serum cholesterol elevations. Effective treatment (behavior therapy and/or treatment with a selective serotonin reuptake inhibitor [SSRI]) seems to decrease cholesterol levels, especially in patients with pathological cholesterol elevations.

scholarly journals Beta Adrenoceptor Polymorphism and Clinical Response to Sertraline in Major Depressive Patients

2017 ◽  
Vol 20 ◽  
pp. 1 ◽  
Author(s):  
Negar Firouzabadi ◽  
Roshanak Raeesi ◽  
Kamiar Zomorrodian ◽  
Ehsan Bahramali ◽  
Ilnaz Yavarian
Keyword(s):  
Clinical Response ◽  
Rating Scale ◽  
Response To Treatment ◽  
Noradrenergic System ◽  
Newly Diagnosed ◽  
Major Depressive ◽  
Beta Adrenoceptor ◽  
Receptor Signalling ◽  
Depressive Patients ◽  
Hamilton Rating Scale

Purpose: The adrenoceptor family, as one of the main contributors in regulating the noradrenergic system, has been studied in involvement of depression and its treatment. A functional polymorphism of G1165C on beta adrenoceptor (βAR) enhances post receptor signalling and is assumed to be involved in pharmacotherapy of depression. The aim of the present study was to discern the influence of G1165C polymorphism in the β1AR gene on individual differences in response to sertraline. Methods: One hundred newly diagnosed patients completed 6 weeks of sertraline treatment. Response to treatment was defined as a 50% decrease in Hamilton Rating Scale for depression (HRSD). Results: The patients who carried CC genotype responded five times more to sertraline comparing with other variants (P=0.005; OR=5.7; 95%CI=1.4-23.9). Moreover, carriers of C allele responded three times more to sertraline than patients with the G allele (P=0.001; OR= 3.3; 95%CI= 1.72-6.50). Conclusion: In conclusion, our results support the hypothesis that genetic variation of β1AR might influence clinical response to sertraline. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

Elevated Cholesterol Levels Associated With Nonresponse to Fluoxetine Treatment in Major Depressive Disorder

2002 ◽  
Vol 43 (4) ◽  
pp. 310-316 ◽  
Author(s):  
Shamsah B. Sonawalla ◽  
George I. Papakostas ◽  
Timothy J. Petersen ◽  
Albert S. Yeung ◽  
Megan M. Smith ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Major Depressive ◽  
Cholesterol Levels ◽  
Fluoxetine Treatment ◽  
Elevated Cholesterol
Sign in / Sign up

Export Citation Format

Share Document